Advancing discovery through Alluvi research
Alluvi Labs specializes in creating and testing high-quality peptides and supplements.
Each product is crafted solely for regulated research and development, with a foundation in scientific rigor.
Alluvi Labs
Designed for scientific accuracy
Retatrutide---Pre--Filled Pen Evaluation
Part of Alluvi Lab’s ongoing research program into advanced GLP multi-agonist compounds.
This formulation is supplied incontrolled batches for laboratory analysis of stability, compound behaviour, and injector system performance
Track. Dose. Progress
The Alluvi app supports wellness goals with smart tracking, log nutrition, monitor weight, and stay consistent through a modern mobile dashboard
Recovery Meets Routine
Daily gummy supplements crafted for sleep, stress, support and muscle recovery, for rest and protein for strength, all in a clean and delicious form
Power-up in a Gummy
A delicious way to fuel your body with protein and creatine–Alluvi Gummy bears are a quick, convenient solution to stay on top of daily nutrients. No scoops. No Shakes. Just results
No prep. No hassle. Just precision dosing.
Alluvi pens are supplied ready-to-use – no mixing, no guesswork.
Developed for controlled research applications, each unit features fixed pre-measured volumes to support consistency and reliability during laboratory evaluation.
Not for human or veterinary consumption.
Track Data. Refine Research.
From peptide pens to supplement gummies, Alluvi provides tools that streamline data collection, organized logging, and weekly progress summaries — ensuring reliable assessment within structured research and development settings.
Not intended for human or animal consumption.
Validated Insights. Grounded in Science.
Independent studies have examined GLP-1 multi-agonist compounds under controlled settings.
Alluvi provides Retatrutide pens solely for laboratory-based research and development.
Not intended for human or veterinary use.
All data originates from third-party published research and is presented for academic reference only. All Alluvi products are distributed strictly for laboratory research purposes
22.5%
Average weight reduction observed with Retatrutide.
Figure referenced from published research on GLP-1 multi-agonist compounds.
Shared strictly for scientific context.
600
Clinical trial based on a 600-calorie daily reduction.
Participants naturally consumed fewer calories without prescribed dieting, linked to reduced appetite and enhanced satiety signaling.
Provided solely as academic context.
28%
Reported improvement in energy levels during trials.
Value documented in published studies on GLP-1 multi-agonist compounds.
Shared only as a scientific reference.
18.3 KG
Average body weight loss reported over a 48-week clinical trial using high-dose Retatrutide.
Cited as an example data point from peer-reviewed research on GLP-1 multi-agonists.
Alluvi does not market or suggest medical use of its products.
The Alluvi AI App is Coming Soon
Start your free trial soon and see how easy it is to track, manage, and optimize your time.
